文献速递儿童青少年精神心境障碍

哌甲酯治疗与自杀未遂风险的关联

Association of Risk of Suicide Attempts With Methylphenidate Treatment.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

哌甲酯治疗前90天自杀未遂风险升高(IRR 6.55),治疗开始后90天内仍升高(IRR 3.91),持续治疗期回落至基线水平;结果不支持哌甲酯与自杀未遂的因果关系。

要点

  • 哌甲酯治疗前90天自杀未遂风险显著升高(IRR 6.55,95%CI 3.37-12.72)。
  • 治疗开始后90天内风险仍升高(IRR 3.91,95%CI 1.62-9.42),持续治疗期回落至基线。
  • 治疗前风险升高可能反映触发就医的新发精神症状,不支持因果关联。

核心结论

  • 哌甲酯治疗前及治疗初期自杀未遂风险升高,持续治疗期回落至基线,结果不支持哌甲酯与自杀未遂的因果关系。

主要发现

  • 哌甲酯启用前90天自杀未遂风险升高,IRR为6.55(95%CI 3.37-12.72)。
  • 治疗最初90天IRR为3.91(95%CI 1.62-9.42),持续治疗期回落至基线水平(IRR 1.35,95%CI 0.77-2.38)。
  • 治疗最初90天与首次治疗前90天相比,自杀未遂发生率未升高(IRR 0.78,95%CI 0.26-2.35)。

临床怎么用

  • 临床应关注ADHD患者在启动哌甲酯治疗前及治疗初期的自杀风险,及时评估精神症状。
  • 持续哌甲酯治疗期间自杀未遂风险未升高,结果不支持因自杀风险而避免使用哌甲酯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeutic use and suicide is unclear. OBJECTIVE: To investigate the association between methylphenidate and the risk of suicide attempts. DESIGN, SETTING, AND PARTICIPANTS: A population-based, electronic medical records database from the Hong Kong Clinical Data Analysis & Reporting System was used to identify 25 629 individuals aged 6 to 25 years who were treated with methylphenidate between January 1, 2001, and December 31, 2015. Those who had attempted suicide were included in the analysis. A self-controlled case series design was used to control for time-invariant characteristics of the patients. MAIN OUTCOMES AND MEASURES: Relative incidence of suicide attempt during periods when patients were exposed to methylphenidate compared with nonexposed periods. RESULTS: Among 25 629 patients with methylphenidate prescriptions, 154 had their first recorded suicide attempt within the study period; of these individuals, 111 (72.1%) were male; mean (SD) age at baseline was 7.15 (2.19) years. The overall incidence of suicide attempts during methylphenidate treatment was 9.27 per 10 000 patient-years. An increased risk of suicide attempts was detected during the 90-day period before methylphenidate was initiated, with an incidence rate ratio (IRR) of 6.55 (95% CI, 3.37-12.72). The IRR remained elevated during the first 90 days of treatment (IRR, 3.91; 95% CI, 1.62-9.42) before returning to baseline levels during ongoing treatment (IRR, 1.35; 95% CI, 0.77-2.38). When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of suicide attempts was not elevated (IRR, 0.78; 95% CI, 0.26-2.35). CONCLUSIONS AND RELEVANCE: The incidence of suicide attempts was higher in the period immediately before the start of methylphenidate treatment. The risk remained elevated immediately after the start of methylphenidate treatment and returned to baseline levels during continuation of methylphenidate treatment. The observed higher risk of suicide attempts before treatment may reflect emerging psychiatric symptoms that trigger medical consultations that result in a decision to begin ADHD treatment. Therefore, this study's results do not support a causal association between methylphenidate treatment and suicide attempts.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Man KKC, Coghill D, Chan EW, et al. Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry. 2017. PMID: 28746699. doi:10.1001/jamapsychiatry.2017.2183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。